Heparin-Induced Overexpression of Basic Fibroblast Growth Factor, Basic Fibroblast Growth Factor Receptor, and Cell-Associated Proteoheparan Sulfate in Cultured Coronary Smooth Muscle Cells
- 1 August 1996
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 16 (8) , 1063-1069
- https://doi.org/10.1161/01.atv.16.8.1063
Abstract
Basic fibroblast growth factor (bFGF), a potent mitogen for arterial smooth muscle cells (SMCs), plays a pivotal role in the pathogenesis of arteriosclerosis and restenosis. Heparin in nanogram quantities may promote or even be required for binding of bFGF to its cognate receptor. Conversely, heparin in microgram doses is a strong inhibitor of arterial SMC replication in vitro and in vivo. Bovine coronary SMCs (cSMCs) express bFGF, bFGF receptor (FGF-R1), and cell membrane–integrated proteoheparan sulfate (HSPG). These three molecules are known to form a trimolecular complex that promotes signal transduction and mitogenesis. The bFGF synthesized by cSMCs is distributed to an intracellular and a pericellular compartment. Resting cultured cells retain about 80% of their bFGF intracellularly; 20% is found in the pericellular region. During proliferation, 70% to 80% of total bFGF is expressed in the pericellular compartment. Trypsinization generates soluble forms of the complex of bFGF with the ectodomains of the bFGF receptor and cell membrane–integrated HSPG in the pericellular compartment, thus allowing quantification of pericellular bFGF by a highly specific enzyme immunoassay. Standard heparin inhibits the proliferation of cSMCs by up to 80% in a concentration range between 10 and 100 μg/mL medium in a dose-dependent manner but increases the protein content of cSMCs compared with proliferating control cells. The heparin-induced increase in cellular protein content includes a 60% to 100% increase in the expression of pericellular bFGF, FGF-R1, and cell membrane–integrated HSPG. Thus, under heparin treatment, the heparan sulfate side chains of cell membrane–integrated HSPG incorporate more [35S]sulfate, and the proportion of [35S]heparan sulfate among total glycosaminoglycans increases from 36% to 52%. Fluorescence-activated cell sorting analysis and [3H]thymidine incorporation experiments provide evidence for multiple effects of heparin, including blocks at early and late checkpoints of the cell cycle in heparin-treated cells. These results indicate that heparin, despite its antiproliferative potency, stimulates the expression of all components of the bFGF system even in coronary SMCs in which growth is inhibited.Keywords
This publication has 28 references indexed in Scilit:
- Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factorGlycobiology, 1994
- Heparin does not inhibit oncogene induction in rabbit aorta following balloon denudationCardiovascular Research, 1993
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor.Journal of Clinical Investigation, 1992
- Heparin stimulates proteoglycan synthesis by vascular smooth muscle cells while supressing cellular proliferationAtherosclerosis, 1992
- Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells [published erratum appears in J Cell Biol 1990 Mar;110(3):863]The Journal of cell biology, 1989
- THE HEPARIN-BINDING (FIBROBLAST) GROWTH FACTOR FAMILY OF PROTEINSAnnual Review of Biochemistry, 1989
- Cell-associated proteoheparan sulfate from bovine arterial smooth muscle cellsExperimental Cell Research, 1988
- Binding and internalization of heparin by vascular smooth muscle cellsJournal of Cellular Physiology, 1985
- Cultured endothelial cells produce heparinlike inhibitor of smooth muscle cell growthThe Journal of cell biology, 1981